The aim of this prospective study is to elucidate whether copeptin could be used as a marker for prognosis and severity of aSAH in a Dutch intensive care population?
ID
Source
Brief title
Condition
- Central nervous system vascular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
One year poor fuctional outcome measured by the Glasgow Outcome Sclae (GOS
1-3).
Secondary outcome
Development of vasospasm, case fatility 30 days after admission, mortality
after one year, functional outcome 12 months after aSAH, assessed by the
Glasgow Outcome Scale and modified Ranking Scale.
Background summary
Subarachnoid haemorrhage from a ruptured cerebral aneurysm (aSAH) is a
significant cause of mortality and morbidity throughout the world. Multiple
clinically grading scales are developed to indicate the severity of
neurological injury, and to provide prognostic information regarding outcome.
However, prediction of outcome remains difficult and complicates decision
making for active treatment. Copeptin, the C-terminal part of the arginine
vasopressin precursor peptide, is associated with the severity and outcome of
critical illness. Recently it has been reported that initial high levels of
plasma copeptin are highly predictive for poor outcome and vasospasm in
patients presenting with aSAH in the Chinese population.
Study objective
The aim of this prospective study is to elucidate whether copeptin could be
used as a marker for prognosis and severity of aSAH in a Dutch intensive care
population?
Study design
A single center prospective observational study
Study burden and risks
one extra laboratory sample taken and a questionary after one year
No extra risks
Hilvarenbeekseweg 60
Tilburg 5022 GC
NL
Hilvarenbeekseweg 60
Tilburg 5022 GC
NL
Listed location countries
Age
Inclusion criteria
* Admission to the intensive care of the St. Elisabeth Hospital Tilburg
* Age 18 year or over
* Start clinical symptoms of SAH within 24hr of at admission to the hospital.
AND
* Informed consent to participate in the trial
* Aneurysm confirmed by computerized tomography angiography (CT-A) with or without digital substraction angiography (DSA).
* Blood drawn after obtaining informed consent on the first 24 hours of admission at de ICU.
Exclusion criteria
* Less than 18 years of age
* Severe language barrier, unable to read the informed consent
* SAH due to non- aneurysmal causes
* Recent ischemic or hemorrhagic stroke
* Recent intracerebral hemorrhage without subarachnoid blood
* Recent previous head trauma
* recent acute myocardial infarction (AMI)
Chronic heart failure
* recent acute exacerbation of COPD (AECOPD)
Chronic liver cirrhosis
Recent acute pancreatitis
Recent sepsis/septic shock
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL45096.008.13 |
| OMON | NL-OMON22580 |